Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RIGL
RIGEL PHARMACEUTICALS, INC.
NASDAQ
$46.48
▼ DOWN 0.81% (-0.38)

KEY STATISTICS

Market Cap$859.98 M
52w High$52.24
52w Low$24.95
Dividend Yield—
Frequency—
P/E11.86
Volume246.11K
Shares Out.18.50M

COMPANY

LEADERSHIP

Raul R. Rodriguez
CHIEF EXECUTIVE
Raul R. Rodriguez

COMPENSATION 2026

Salary$0
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$0

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 29, 2000
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
173

PRICE TARGET

Target High$85.00
Target Low$49.00
Target Median$67.00
Target Consensus$67.00

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$80.10M
NOV
3
TUE

SPLIT RECORD

DATETYPERATIO
2024-06-27Reverse1:10
2003-06-25Reverse1:9

PRICE

$46.48 ▼ DOWN 0.81% (−$0.38)
OVERLAYS
$45.90$46.20$46.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM46.48

About Rigel Pharmaceuticals, Inc.

https://www.rigel.com ↗

Rigel Pharmaceuticals develops small molecule drugs for hematologic, cancer, and immune diseases, including Tavalisse and Fostamatinib, with ongoing clinical trials and collaborations with major pharma companies.

INDUSTRY

Biotechnology

A PRODUCT RIGEL PHARMACEUTICALS, INC. IS KNOWN FOR

GAVRETO® (pralsetinib)
GAVRETO® (pralsetinib)

GAVRETO is a once-daily oral treatment for adults with RET-positive metastatic non-small cell lung cancer, and its 2024 acquisition and commercialization aim to bolster Rigel's oncology portfolio.

COMPETITORS

COMPETITOR
AMGN COMPARE
EXEL COMPARE
LLY COMPARE
NVS COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Gross Product— — $75.39M $88.46M ▲
Gross product sales$85.62M — — —
Product— — $54.92M $67.02M ▲
Product sales net$64.07M — — —
Contract revenues from collaborations$5.39M $4.12M ▼$3.9M ▼$11.69M ▲
Development Milestones— — — $4M
Milestone$3M — — —
Discounts and allowances-$21.56M $0 ▲-$20.46M ▼-$21.45M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
116
LISTED HERE
24
RANKED BY POSITION SIZE
AVUV
0.12% · 782.0K
XBI
0.27% · 693.6K
VTS.AX
0.00% · 555.8K
IWM
0.03% · 475.7K
VETS
0.14% · 113.6K
SCHA
0.02% · 88.4K
BSVO
0.16% · 83.0K
FDM
1.41% · 81.2K
FESM
0.04% · 56.7K
PSC
0.09% · 54.4K
BBP
1.75% · 44.6K
DFAS
0.01% · 32.7K
GSSC
0.13% · 31.4K
JPSE
0.23% · 29.2K
LABU
0.19% · 25.2K
SBIO
0.44% · 22.9K
EES
0.12% · 18.2K
XRS2.F
0.03% · 17.0K
PRFZ
0.02% · 14.5K
RSSL
0.03% · 8.7K
FSML
0.11% · 3.7K
RTWO.L
0.05% · 2.2K
URTY
0.01% · 748
RESM
0.03% · 35

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
277
TOP 12 OF 277 · RANKED BY POSITION SIZE
Oppenheimerfunds, Inc.
5.0M sh · $12.85M
Blackrock Fund Advisors
4.4M sh · $10.43M
Blackrock Institutional Trust Company, N.A.
3.4M sh · $8.07M
Blackrock, Inc.
1.9M sh · $75.89M
Soleus Capital Management, L.P.
1.8M sh · $72.12M
Armistice Capital, LLC
1.7M sh · $65.41M
Blackrock Inc.
1.5M sh · $12.44M
State Street Corp
1.1M sh · $30.29M
Vanguard Group Inc
1.0M sh · $29.55M
American Century Companies Inc
741.7K sh · $29.02M
Goldman Sachs Group Inc
737.0K sh · $20.88M
Lsv Asset Management
721.7K sh · $28.23M

RATINGS SNAPSHOT

Overall rating: A-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets5
Debt To Equity3
Price To Earnings3
Price To Book3
Overall Score4

INSIDER TRADES

★
OFFICER: EVP, CHIEF MEDICAL OFFICER
HANNAH ALISON L.
Purchase · 24.4K shares
2026-07-08
★
DIRECTOR
Ali-Jackson Kamil
Sale · 2.5K shares
2026-06-22
★
OFFICER: EVP, CHIEF COMMERCIAL OFFICER
Santos David A
Purchase · 7.4K shares
2026-06-17
★
OFFICER: EVP & CHIEF FINANCIAL OFFICER
Schorno Dean L
Purchase · 7.4K shares
2026-06-17

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
NEUTRAL 2
5 GRADES IN THE LAST 12 MONTHS
Piper Sandler NEUTRAL HC Wainwright & Co. BUY Citigroup BUY Cantor Fitzgerald NEUTRAL Jefferies BUY

SECTORS PEERS

PEERPRICE
OMER$18.61COMPARE
CRVS$14.16COMPARE
OLMA$10.27COMPARE
FDMT$14.67COMPARE
PRTA$9.33COMPARE
BCYC$4.20COMPARE
AKBA$0.88COMPARE
GOSS$0.17COMPARE